Assistant Professor of Medicine, Massachusetts General Hospital
Oncology
Dr. Rebecca S. Heist, MD
|
|
Give Review
Doctor Rebecca S. Heist, MD practices Oncology. She went to medical school at Harvard Medical School. Harvard Medical School is a one of the best medicals schools. Harvard Medical School is ranked 1/12 in Research/PrimaryCare. Doctor Rebecca S. Heist, MD is a published physician as well. She has 65 publications published. The latest was: Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. She is registered with Medicare and accepts Medicare payments.
Publications
- Molecularly targeted therapies in non-small-cell lung Cancer annual update 2014.
- Polymorphisms in MicroRNAs Are Associated with Survival in Non-Small Cell Lung Cancer.
- The Prognostic Impact of KRAS, Its Codon and Amino Acid Specific Mutations, on Survival in Resected Stage I Lung Adenocarcinoma.
- Genotyping Lung Cancer Is an Investment in the Future.
- Inflammation-related Genetic Variations and Survival for Advanced Non-Small Cell Lung Cancer Receiving First-line Chemotherapy.
- Failure to induce apoptosis via BCL-2 family proteins underlies lack of efficacy of combined MEK and PI3K inhibitors for KRAS mutant lung Cancers.
- Invasive adenocarcinoma of the Lung is associated with the upper Lung regions.
- CALGB 30704 (Alliance): A randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of adva...
- Treatment-related toxicities in a phase II trial of dasatinib in patients with squamous cell carcinoma of the Lung.
- Adjuvant Therapy for a 3.9-cm Adenocarcinoma of the Lung.
- The Impact of EGFR Mutation Status on Outcomes in Patients With Resected Stage I Non-Small Cell Lung Cancers.
- Multidisciplinary Management of Small Cell Lung Cancer.
- Tumor islands in resected early-stage Lung adenocarcinomas are associated with unique clinicopathologic and molecular characteristics and worse prognosis.
- FGFR1 Amplification in Squamous Cell Carcinoma of The Lung.
- Detection of novel actionable genetic changes in Salivary duct carcinoma helps direct patient treatment.
- A Phase I Study of Erlotinib and Hydroxychloroquine in Advanced Non-Small-Cell Lung Cancer.
- Genetic changes in squamous cell lung Cancer: a review.
- Depression and survival in metastatic non-small-cell lung Cancer: effects of early palliative care.
- SnapShot: Non-Small Cell Lung Cancer.
- Effect of Early Palliative Care on Chemotherapy Use and End-of-Life Care in Patients With Metastatic Non-Small-Cell Lung Cancer.
- Implementing multiplexed genotyping of non-small-cell lung Cancers into routine clinical practice.
- Cigarette smoking increases copy number alterations in nonsmall-cell lung Cancer.
- Tumor Epidermal Growth Factor Receptor Genotype and Depression in Stage IV Non-Small Cell Lung Cancer.
- Interactions between environmental factors and polymorphisms in angiogenesis pathway genes in Esophageal adenocarcinoma risk: a case-only study.
- No evidence of an association of ERCC1 and ERCC2 polymorphisms with clinical outcomes of platinum-based chemotherapies in non-small cell lung Cancer: a meta-analysis.
- Association between polymorphisms in Cancer-related genes and early onset of esophageal adenocarcinoma.
- Interactions between genetic polymorphisms in the apoptotic pathway and environmental factors on Esophageal adenocarcinoma risk.
- Genotypic and histological evolution of lung Cancers acquiring resistance to EGFR inhibitors.
- Impact on disease development, genomic location and biological function of copy number alterations in non-small cell lung Cancer.
- Cetuximab monotherapy in patients with advanced non-small cell lung Cancer after prior epidermal growth factor receptor tyrosine kinase inhibitor therapy.
- Phase I/II study of AT-101 with topotecan in relapsed and refractory small cell lung Cancer.
- A Large-scale genetic association study of Esophageal adenocarcinoma risk.
- Interactions among genetic variants in apoptosis pathway genes, reflux symptoms, body mass index, and smoking indicate two distinct etiologic patterns of Esophageal ad...
- Code status documentation in the outpatient electronic medical records of patients with metastatic Cancer.
- p53 Arg72Pro, MDM2 T309G and CCND1 G870A polymorphisms are not associated with susceptibility to Esophageal adenocarcinoma.
- Clinical features and outcome of patients with non-small-cell lung Cancer who harbor EML4-ALK.
- Brief report of biweekly pemetrexed and gemcitabine in elderly patients with non-small cell lung Cancer.
- Cisplatin pharmacogenetics, DNA repair polymorphisms, and esophageal Cancer outcomes.
- Epidermal growth factor A61G gene polymorphism, gastroEsophageal reflux disease and Esophageal adenocarcinoma risk.
- Vascular endothelial growth factor polymorphisms and esophageal Cancer prognosis.
- Genome-wide analysis of survival in early-stage non-small-cell lung Cancer.
- p53 Arg72Pro and MDM2 T309G polymorphisms, histology, and esophageal Cancer prognosis.
- Matrix metalloproteinase 1, 3 and 12 polymorphisms and Esophageal adenocarcinoma risk and prognosis.
- EGFR-targeted therapies in lung Cancer: predictors of response and toxicity.
- Circulating 25-hydroxyvitamin D, VDR polymorphisms, and survival in advanced non-small-cell lung Cancer.
- Genetic polymorphisms of VEGF, interactions with cigarette smoking exposure and Esophageal adenocarcinoma risk.
- Polymorphisms of the NER pathway genes, ERCC1 and XPD are associated with Esophageal adenocarcinoma risk.
- Apoptosis gene polymorphisms, age, smoking and the risk of non-small cell lung Cancer.
- A phase II study of oxaliplatin, pemetrexed, and bevacizumab in previously treated advanced non-small cell lung Cancer.
- MDM2 promoter polymorphism and pancreatic Cancer risk and prognosis.
- Epidermal growth factor receptor polymorphisms and clinical outcomes in non-small-cell lung Cancer patients treated with gefitinib.
- A phase II study of gefitinib in patients with advanced thyroid Cancer.
- Polymorphisms of inflammatory and metalloproteinase genes, Helicobacter pylori infection and the risk of oEsophageal adenocarcinoma.
- VEGF polymorphisms and survival in early-stage non-small-cell lung Cancer.
- Genetic polymorphisms of MDM2, cumulative cigarette smoking and nonsmall cell lung Cancer risk.
- Vascular endothelial growth factor genotypes, haplotypes, gender, and the risk of non-small cell lung Cancer.
- A rapid outcomes ascertainment system improves the quality of prognostic and pharmacogenetic outcomes from observational studies.
- Should oncologists measure the mRNA and protein expression levels of ERCC1 and RRM1 in non-small-cell lung Cancer?
- MDM2 polymorphism, survival, and histology in early-stage non-small-cell lung Cancer.
- Circulating 25-hydroxyvitamin D levels predict survival in early-stage non-small-cell lung Cancer patients.
- Second hand smoke exposure and survival in early-stage non-small-cell lung Cancer patients.
- Polymorphisms of vitamin D receptor and survival in early-stage non-small cell lung Cancer patients.
- Matrix metalloproteinase polymorphisms and survival in stage I non-small cell lung Cancer.
- Smoking cessation before diagnosis and survival in early stage non-small cell lung Cancer patients.
Schools
Harvard Medical School
Massachusetts General Hospital
Dana Farber Cancer Institute
Procedures Preformed
- Thoracentesis
Conditions Treated
- Adrenal Gland Cancer
- Anemia
- Bladder Cancer
- Breast Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Education
-
Massachusetts General Hospital -
Harvard Medical School
Hospital
-
Massachusetts General Hospital
Drug Facts
| NPI NUMBER | 1184697278 | |
| NPPES Provider LastName | HEIST | |
| NPPES Provider FirstName | REBECCA | |
| NPPES Provider ZIPCode | 021142620 | |
| NPPES Provider State | MA | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 224.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 11.0 | |
| Percent Opioid Claims | 4.91 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1184697278 |
| Last Name Of The Provider | HEIST |
| First Name Of The Provider | REBECCA |
| View All |
Similar Doctors
|
|
Dr. Lori J. Wirth, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Leroy M. Parker, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. M S. Donnelly, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Philip J. Saylor, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Gregory J. Britt, MD
This Doctor is OpenDoctor Recommended.
|